) is highly dependent on Qsymia (proposed trade name in the EU:
Qsiva) for growth. The drug was launched in the U.S. in Sep 2012
as an adjunct to a healthy diet (low on calories) and increased
physical activity for chronic weight management in obese (Body
Mass Index or BMI - 30 or more) or overweight (BMI - 27 or more)
adults suffering from at least one weight-related co-morbid
However, Qsymia has performed disappointingly since launch.
Qsymia revenues in the second quarter of 2013 were $5.5 million
compared with $4.1 million in the first quarter of 2013.
In order to boost Qsymia revenues, VIVUS is evaluating the drug
for other indications including type II diabetes. Encouraging new
data on Qsymia was published in an online edition of Diabetes
Care. Data from the two-year SEQUEL study (n = 475) comparing
Qsymia to placebo was analyzed by the publication. The study
enrolled high-risk patents including overweight or obese patients
with pre-diabetes or metabolic syndrome.
A considerable reduction in progression to type II diabetes and
significant weight loss were observed in patients receiving
Qsymia. Annualized incidence rate of type II diabetes declined by
70.5% and 78.7% at two Qsymia treated dosages of 7.5mg/46mg and
15mg/92mg, respectively, when compared to placebo.
The diabetes market is very crowded with key players like
) among others.
VIVUS, a biopharmaceutical company, currently carries a Zacks
Rank #3 (Hold). Biopharma companies that currently look
) with a Zacks Rank #1 (Strong Buy).
ACTELION LTD (ALIOF): Get Free Report
MERCK & CO INC (MRK): Free Stock Analysis
NOVO-NORDISK AS (NVO): Free Stock Analysis
VIVUS INC (VVUS): Free Stock Analysis Report
To read this article on Zacks.com click here.